Filing Details

Accession Number:
0000950170-24-041426
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-03 19:33:35
Reporting Period:
2024-04-01
Accepted Time:
2024-04-03 19:33:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1745999 Beam Therapeutics Inc. BEAM Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1786322 Giuseppe Ciaramella C/O Beam Therapeutics Inc.,
238 Main Street
Cambridge MA 02142
President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-04-01 4,534 $32.12 169,616 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-04-03 27,318 $0.00 27,318 $0.67
Common Stock Stock Option (Right to Buy) Acquisiton 2024-04-03 12,979 $0.00 12,979 $4.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,318 2024-04-03 2028-05-08 No 4 A Direct
12,979 2024-04-03 2029-02-13 No 4 A Direct
Footnotes
  1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares.
  4. On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares.